Alba Bioscience, Inc.

Alba Bioscience, Inc., a Chicago-based subsidiary of Quotient Biodiagnostics, Inc., manufactures and supplies immunohematology reagents and blood banking diagnostics to the federal government as a prime contractor, competing predominantly without set-aside designations across full-and-open procurement vehicles.

The company's core capability portfolio centers on in vitro diagnostic products and blood banking materials: monoclonal antibodies (ALBACLONE branded), antibody identification and screening panels in multiple cell configurations, quality control kits (ALBASURE), additive solutions (ALBAHANCE), and specialized cell reagents (ALBACYTE). These products support blood typing, transfusion services, and antibody screening operations across federal healthcare systems. Representative work includes a $54,925 BPA call from Veterans Integrated Service Network 19 for blood bank transfusion reagents (June 2025, GSA Schedule 65-VII), a $200,142 BPA call from VISN 15 for blood bank reagents with completion by May 31, 2026 (June 2025), and numerous Defense Logistics Agency Medical Supply Chain delivery orders for individual reagent products ranging from $38 to $15,944 in value, issued monthly across 2025 and early 2026.

Customer concentration is stark and decisively centered on the Defense Logistics Agency's Medical Supply Chain: 2,360 awards (92% of all awards) carrying $17.9 million in combined potential value. Veterans Affairs represents the second-tier customer base, with VISN 16, VISN 17, VISN 19, and VISN 23 each holding 16 to 42 awards; however, by potential value, VISN 12 anchors $5.7 million across two awards, and VISN 15 carries $3.6 million across fifteen awards. The Air Force Education and Training Command and Defense Health Agency round out the active set. The concentration signal is reinforced by a secondary ranking split: DLA's volume and dollar dominance in the first ranking contrasts with VISN 12's smaller award count but larger per-award value, suggesting strategic buys by VA facilities for larger supply commitments.

Alba Bioscience holds position on the GSA Schedule 65-VII for In Vitro Diagnostics, Reagents, and Tests, the primary vehicle through which its federal work flows. The schedule carries 251 task orders valued at $11.8 million combined. Two single-award Blanket Purchase Agreements with the VA underpin much of the supply relationship: a $199.7 million ceiling BPA with VISN 15 awarded June 1, 2025, extending through May 31, 2030 (two BPA calls issued to date), and a $218.8 million ceiling BPA with VISN 10 awarded October 1, 2024, running through September 30, 2026. Beyond GSA Schedule 65-VII, Alba Bioscience sits on DLA's Medical Capital Equipment Program (1,083 task orders, $1.6 million combined potential value) and two Defense IDIQs (Indefinite Delivery Contracts SPE2DE22D0008 and SPM2DE13D7348 with 973 and 301 task orders respectively).

Activity has remained stable to slightly declining: 265 awards in 2024, 221 in 2025, and 74 through early June 2026. The recompete cliff within the next twenty-four months involves thirteen awards carrying $639 thousand in combined potential value, representing manageable transition exposure. Alba Bioscience operates as a pure prime contractor—zero subcontract footprint across the award record—meaning no teaming relationships surface in the source data.

Alba Bioscience competes without small-business preferences across its entire footprint, reflecting the specialized and differentiated nature of its immunohematology product portfolio. The company's federal positioning is highly concentrated in routine, high-volume supply orders to DLA and routine BPA calls to VA networks, with no defense prime relationships, no set-aside leverage, and no strategic teaming. Category concentration is extreme: 2,360 awards fall under NAICS 424210 (Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers), and 2,414 awards carry PSC code 6515 (Laboratory Equipment and Supplies). The business model is essentially single-channel distribution of specialized blood banking reagents to federal healthcare procurement systems.

Our expertise in blood grouping reagents, antibody screening, and donor testing enables healthcare professionals to ensure accurate and reliable transfusion compatibility, ultimately improving patient safety and care.